B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Conditions
Brief summary
This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as alvocidib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Detailed description
PRIMARY OBJECTIVES: I. Determine the toxicity profile, dose-limiting toxicity, and maximum tolerated dose of flavopiridol (alvocidib) as consolidation chemotherapy after cytoreduction chemotherapy in patients with B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. SECONDARY OBJECTIVES: I. Determine the pharmacokinetics and cellular pharmacodynamics of flavopiridol in these patients. II. Determine the complete response (CR) and overall response rate (CR and partial response) of patients treated with flavopiridol. OUTLINE: This is a dose-escalation study. Patients receive alvocidib intravenously (IV) over 30 minutes (loading dose), followed by alvocidib IV over 4 hours on days 1, 8, and 15. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 12 patients are treated at the MTD (i.e., recommended phase II dose). Patients undergo blood collection at baseline and periodically during study for pharmacokinetic and cytokine studies (levels of tumor necrosis factor-alpha, interleukin \[IL\]-6, -11, and -16) by enzyme-linked immunosorbent assay (ELISA). Interphase cytogenetics, p53 mutational status, p53/ATM function, V\_H mutational status, zeta-chain-associated protein kinase 70 (ZAP-70) overexpression, and single nucleotide polymorphisms are also examined. After completion of study treatment, patients are followed at 2 months and then every 3 months for 5 years.
Interventions
OTHERlaboratory biomarker analysis
Correlative studies
OTHERpharmacological study
Correlative studies
DRUGalvocidib
Given IV
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of 1 of the following: * B-cell chronic lymphocytic leukemia (CLL) * Small lymphocytic lymphoma (SLL) * Must have received 1-3 prior therapies for CLL * Completed therapy 2-12 months ago * Prior therapy must have led to a partial response or greater * No evidence of progressive disease * ECOG performance status 0-2 * Absolute neutrophil count ≥ 1,000/mm³ * WBC ≤ 5,000/mm³ * Platelet count ≥ 50,000/mm³ * Cytopenia allowed * Creatinine \< 2.0 mg/dL * Bilirubin ≤ 1.5 times normal (unless due to Gilbert's disease or hemolysis) * AST ≤ 2 times normal (unless due to hemolysis) * No secondary malignancy or other disease that would limit survival to \< 2 years * No history of inflammatory bowel disease unless inactive for \> 2 years * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * See Disease Characteristics * No other concurrent chemotherapy * No concurrent radiotherapy * No concurrent dexamethasone or other corticosteroid-based antiemetics * No concurrent chronic corticosteroid therapy * No other concurrent hormonal therapy except for the following: * Steroids for new adrenal failure * Hormones for nondisease-related conditions (e.g., insulin for diabetes)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity profile of alvocidib administered as a 30 minute loading dose followed by a 4-hour infusion once weekly for 3 consecutive weeks every 5 weeks as consolidation therapy following cytoreduction chemotherapy | Day 1, every 2 courses, at 2 months and then every 3 months for 5 years after completion of study treatment | Assessed utilizing the NCI Common Terminology Criteria for Adverse Events version 3.0. |
| Dose-limiting toxicity of alvocidib as consolidation chemotherapy after cytoreduction chemotherapy in patients with B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma | Course 1 | The National Cancer Institute Common Toxicity Criteria version 3.0 will be used to characterize toxicity. If no patients experience dose-limiting toxicity, dose escalation will occur. If 1 patient has a dose limiting toxicity, 3 additional patients will be enrolled at that dose. If fewer than 2 of 6 patients experiences dose limiting toxicity, then the next highest dose level will be used for the subsequent cohort of 3 patients. If at any dose level two or more of the six patients experience a dose limiting toxicity, 3 additional patients will be treated at the previous dose level. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics and cellular pharmacodynamics of alvocidib administered in this schedule | Baseline and day 1 | Cytokine studies will be examined by standard ELISA assays to determine if increase IL-6 correlates with hypotension, hypoxemia, and tachycardia observed following treatment and to identify the source of production of this cytokine. We will examine interphase cytogenetics, p53 mutational status, p53/ATM functional assay, VH mutational status, and ZAP-70 over-expression. |
| Complete response (CR) and overall response rate (CR and partial response) of alvocidib in patients with previously-treated CLL | Baseline, every 2 courses, at 2 months and then every 3 months for 5 years after completion of study treatment | Criteria for response will utilize the Revised National Cancer Institute-sponsored Working Group Guidelines. |
Countries
United States
Outcome results
None listed